Cetuximab (Erbitux/C225), an anti-epidermal growth factor receptor (EGFR) human-mouse chimeric immunoglobulinG1 (IgG1) antibody has already been approved for the treatment of head and neck cancers and colon cancer15. This evidence concerns the gene EGFR and digestive system neoplasm.